Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• High-risk acute coronary syndromes often require immediate percutaneous coronary intervention (PCI).
• The efficacy of early platelet inhibition strategies in this setting is not well-established.
• Dual antiplatelet therapy with aspirin and clopidogrel is common, but its effectiveness prior to immediate PCI is uncertain.

Purpose of the Study:

• To compare the efficacy of early dual platelet inhibition (aspirin and clopidogrel) versus triple therapy (aspirin, clopidogrel, and tirofiban).
• To evaluate platelet inhibition and its impact on infarct size in patients undergoing immediate PCI for acute coronary syndromes.
• To assess the effectiveness of clopidogrel pre-treatment before urgent PCI.

Main Methods:

• A randomized study of 100 patients diagnosed with non-ST-segment elevation myocardial infarction.
• Patients received either aspirin plus clopidogrel or aspirin, clopidogrel, plus tirofiban (bolus and infusion).
• Primary endpoint: reduction in infarct size (measured by cardiac troponin T). Secondary endpoints: platelet function and clinical events.

Main Results:

• Tirofiban significantly maximized platelet inhibition compared to dual therapy (p < 0.0001).
• Triple therapy with tirofiban was associated with significantly lower post-PCI cardiac troponin T levels (p = 0.0352).
• Clopidogrel was ineffective in 69% of patients at the time of PCI, and 47% even with >120 minutes pre-treatment.

Conclusions:

• Dual platelet inhibition with clopidogrel and aspirin is often inadequate for patients requiring immediate PCI.
• Tirofiban provides consistent and effective platelet inhibition crucial for immediate or very early invasive therapy.
• Cardiovascular and bleeding event rates were comparable between the groups, suggesting tirofiban's safety in this acute setting.